Mpox Therapeutics - Global Strategic Business Report

The global market for Mpox Therapeutics was estimated at US$90.0 Million in 2024 and is projected to reach US$132.7 Million by 2030, growing at a CAGR of 6.7% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Mpox Therapeutics market.

Global Mpox Therapeutics Market - Key Trends & Drivers Summarized

Why Are Antiviral Treatments Central in Mpox Care?

Antiviral treatments are crucial in managing severe mpox cases and limiting complications. These treatments help reduce viral replication once infection is confirmed. Currently available options include antiviral drugs originally developed for related viruses. Access to effective therapeutics enables clinicians to treat high-risk patients, such as immunocompromised individuals, pregnant persons, and children. Early intervention with antiviral therapy improves patient outcomes and reduces the risk of severe disease progression.

Healthcare providers rely on protocols that guide initiation and dosing of antivirals based on clinical severity. Intravenous or oral regimens are selected according to patient condition and drug availability. Treatment also involves monitoring for side effects and adjusting therapy in response to kidney or liver function. In resource-limited settings, timely access to antiviral stockpiles and clear treatment guidelines remain critical for effective patient management.

What New Treatments Are Emerging or Under Study?

Research into novel therapies has intensified due to rising mpox incidence and growing public health interest. Experimental drugs targeting viral replication mechanisms are in various stages of clinical development. Some candidates offer broader antiviral activity. Others are designed specifically for mpox. Research efforts also include evaluating monoclonal antibodies aimed at neutralizing the virus. These treatments may offer passive immunity and support for severe or refractory cases.

Clinical trials focus on assessing safety, dosing, and efficacy across diverse patient groups. Special attention is given to understanding drug impacts in vulnerable populations such as children, elderly people, and immunosuppressed individuals. Drug developers are also exploring combination therapies that pair antivirals with immune modulators to enhance outcomes. Regulatory agencies have begun granting emergency use authorizations for some treatments, enabling broader access while formal approvals progress.

How Are Access and Distribution Evolving?

Mpox therapeutics are being distributed through public health channels, emergency stockpiles, and international aid programs. Partnerships between government agencies, non-governmental organizations, and manufacturers facilitate medicine allocation in low-resource regions. Programs often include training for clinicians to identify eligible patients, manage treatment regimens, and monitor for adverse events. This coordinated approach helps ensure equitable treatment access in outbreak zones.

Pharmaceutical companies are also scaling production capacities and restructuring supply chains to meet increasing demand. They are exploring flexible manufacturing processes that can quickly adapt volumes as needed. Distribution systems now include temperature-controlled transport, real-time tracking, and regional hubs to reach remote areas efficiently. Such logistics enhancements are vital to avoid stockouts and ensure treatment availability during epidemic peaks.

Growth in the Mpox Therapeutics Market Is Driven by Several Factors

Growth in the mpox therapeutics market is driven by several factors. Rising global mpox cases have increased demand for effective treatments. Emergency authorizations and approvals of new antiviral agents support market expansion. Investment in clinical trials targeting safety and efficacy in vulnerable populations advances therapeutic options. Scale-up of manufacturing capacity and flexible supply chains improves access in diverse settings. Expansion of international aid programs enables distribution in low-resource regions. Growing focus on combination therapies and monoclonal antibodies broadens treatment portfolios and supports future innovation.

Scope Of Study:

The report analyzes the Mpox Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments: Treatment (Smallpox Vaccine, Antivirals, Vaccinia Immune Globulin); End-Use (Hospitals End-Use, Specialty Clinics End-Use, Ambulatory Surgery Centers End-Use, Other End-Uses)

Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Smallpox Vaccine segment, which is expected to reach US$75.5 Million by 2030 with a CAGR of a 5.4%. The Antivirals segment is also set to grow at 9.0% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, estimated at $24.5 Million in 2024, and China, forecasted to grow at an impressive 10.3% CAGR to reach $27.2 Million by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Mpox Therapeutics Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Mpox Therapeutics Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Mpox Therapeutics Market expected to evolve by 2030?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2030?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as Aegis Sciences Corporation, Bavarian Nordic A/S, Baxter International Inc., BioNTech SE, Chimerix Inc. and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 42 companies featured in this Mpox Therapeutics market report include:

• Aegis Sciences Corporation
• Bavarian Nordic A/S
• Baxter International Inc.
• BioNTech SE
• Chimerix Inc.
• CIDIC Company Limited
• Emergent BioSolutions Inc.
• Emcure Pharmaceuticals Ltd.
• Gilead Sciences Inc.
• Hetero Drugs Limited
• Mylan N.V. (Viatris)
• Moderna Inc.
• Olon S.p.A.
• Piramal Enterprises Ltd.
• Pfizer Inc.
• Sanofi S.A.
• SIGA Technologies Inc.
• SymBio Pharmaceuticals Ltd.
• Teva Pharmaceutical Ltd.
• Tonix Pharmaceuticals

This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include:

• Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs.
• Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes segmentation by product, technology, type, material, distribution channel, application, and end-use, with historical analysis since 2015.
• Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends.
• Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape.
• Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players.
• Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities.
• Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage.